Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries-Reference-Cited by-同舟云学术

Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries

Published:2012-04 Issue:4 Volume:31 Page:700-708
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Neumann Peter J.¹,Bliss Sarah K.²,Chambers James D.³

Affiliation:

1. Peter J. Neumann ( ) is director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and a professor of medicine at the Tufts University School of Medicine, in Boston, Massachusetts.

2. Sarah K. Bliss is a research assistant at the Center for the Evaluation of Value and Risk in Health.

3. James D. Chambers is a project director at the Center for the Evaluation of Value and Risk in Health.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference33 articles.

1. Risky feelings: Why a 6% risk of cancer does not always feel like 6%

2. The Relation between Funding by the National Institutes of Health and the Burden of Disease

3. Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans;BioDrugs;2023-04-01

2. The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer;Journal of Pharmaceutical Policy and Practice;2023-02-16

3. Management guideline for the off-label use of medicine in China (2021);Expert Review of Clinical Pharmacology;2022-09-11

4. Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?;Journal of Comparative Effectiveness Research;2021-11

5. Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?;PharmacoEconomics;2021-10-26